Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Retained Earnings: 2021-2025

Historic Retained Earnings for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -$119.0 million.

  • InMed Pharmaceuticals' Retained Earnings fell 7.40% to -$119.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.0 million, marking a year-over-year decrease of 7.40%. This contributed to the annual value of -$117.2 million for FY2025, which is 7.48% down from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' Retained Earnings is -$119.0 million, which was down 1.50% from -$117.2 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Retained Earnings registered a high of -$77.8 million during Q3 2021, and its lowest value of -$119.0 million during Q3 2025.
  • Moreover, its 3-year median value for Retained Earnings was -$109.1 million (2024), whereas its average is -$109.4 million.
  • Data for InMed Pharmaceuticals' Retained Earnings shows a maximum YoY declined of 24.59% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows InMed Pharmaceuticals' Retained Earnings stood at -$82.1 million in 2021, then dropped by 20.65% to -$99.1 million in 2022, then dropped by 6.41% to -$105.4 million in 2023, then fell by 7.51% to -$113.3 million in 2024, then dropped by 7.40% to -$119.0 million in 2025.
  • Its Retained Earnings was -$119.0 million in Q3 2025, compared to -$117.2 million in Q2 2025 and -$115.4 million in Q1 2025.